Create issue ticket

18 Possible Causes for icotinib

  • Thalidomide

    The xenograft mouse model was used to explore the effects of thalidomide and icotinib in vivo.[] RESULTS Treatments of thalidomide and/or icotinib reduced cell viability, induced apoptosis, and suppressed migration.[] MATERIAL AND METHODS Humanized NSCLC cell lines PC9 and A549 were co-cultured with thalidomide and/or icotinib to test for anti-tumor efficiency.[]

  • Pleural Effusion

    INTERVENTIONS: EGFR-TKIs (Icotinib), MET inhibitor crizotinib.[]

  • Vindesine

    […] and Docetaxel) 2 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma Unknown status NCT02103257 Phase[] Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib 4 A Study[] 4 Sequential Icotinib Plus Chemotherapy;Icotinib 3 Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell[]

  • Gemcitabine

    Here, we report the treatment of a 64-year-old male with metastatic pancreatic cancer using a novel regimen of icotinib with gemcitabine.[] This is the first reported case for the treatment of advanced pancreatic cancer with icotinib plus gemcitabine and demonstrates a promising therapeutic alternative.[]

  • Brain Irradiation

    Patients receiving icotinib who had intracranial progression only were switched to WBI plus either icotinib or chemotherapy until further progression; those receiving icotinib[] Icotinib could be continued beyond progression where clinical benefit was observed by the investigator, and crossover to icotinib from WBI was allowed.[] Median intracranial PFS was 10·0 months (95% CI 5·6-14·4) with icotinib versus 4·8 months (2·4-7·2) with WBI (equating to a 44% risk reduction with icotinib for an event of[]

  • Carboplatin

    icotinib.[] The patient's condition had remained stable on pemetrexed and icotinib for more than 20 months, with no evidence of progression.[] INTERVENTIONS: In this case, we reported the successful long-term maintenance treatment of a patient with EGFR wt NSCLC with pemetrexed and Icotinib.[]

  • Liver Metastasis

    KEYWORDS: Adenocarcinoma; EGFR ; Icotinib; TKI ; liver metastasis[] One month later, continued Icotinib treatment was used as magnetic resonance imaging revealed liver metastasis (LM).[] To our knowledge, this is the first report documenting a successful case of an NSCLC patient with LM treated with Icotinib after receiving a radical resection for pulmonary[]

  • Ketoconazole

    Abstract Icotinib (ICO), a novel small molecule and a tyrosine kinase inhibitor, was developed and approved recently in China for non-small cell lung cancer.[] Activation by icotinib was observed with CYP3A-mediated midazolam hydroxylase activity in HLM ( 40% over the baseline) or recombinant human CYP3A5 (rhCYP3A5) ( 70% over the[] (PubChem CID: 22024915); Icotinib; KTZ, ketoconazole (PubChem CID: 456201); Ketoconazole; MDZ, midazolam (PubChem CID: 4192); NIF, nifedipine (PubChem CID: 4458); Phenacetin[]

  • Dehydroepiandrosterone

    Murodermin Nepidermin Transforming growth factor alpha (TGFα) Kinase inhibitors: Afatinib AG-490 Agerafenib Brigatinib Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib[]

  • Leptomeningeal Metastasis

    In addition, another first-generation EGFR-TKI icotinib also showed efficacy on LM from NSCLC with EGFR mutation (Gong et al. 2015 ).[] […] adenocarcinoma, 21 (25%) showed LM at 2–18 months (median, 12 months) after the tyrosine kinase inhibitor (TKI) target therapy, including gefitinib (n   14), erlotinib (n   3), icotinib[] ITC/WBRT/Chemotherapy No EGFR MT NSCLC Icotinib partly Intracranial ORR 8/21; neurological symptoms improved 18/20, PS improved 17/21; median OS 10.1 months Gong et al. ([]

Further symptoms